Renal failure Urological and Genital Diseases Renal failure
Conditions
Interventions
Participants are randomised to one of the following three 8 week interventions through random number generation:
HIIT programme A:
Each session will consist of 16-min
Sponsors
University Hospitals of Leicester NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Male or female, aged 18 years or above 3. Diagnosed with CKD and are a kidney transplant recipient 4. Received kidney transplant > 12 weeks prior to entering the study
Exclusion criteria
Exclusion criteria: 1. Female participants who are pregnant, lactating, or planning pregnancy during the course of the study 2. Scheduled elective surgery or other procedures requiring general anaesthesia during the study 3. Any other significant disease or disorder (i.e. significant co-morbidity including unstable hypertension, potentially lethal arrhythmia, myocardial infarction within 6 months, unstable angina, active liver disease, uncontrolled diabetes mellitus (HbA1c > = 9%), advanced cerebral or peripheral vascular disease) which, in the opinion of the patients own clinician, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study 4. Inability to give informed consent or comply with testing and training protocol for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Recruitment rate is assessed by recording the percentage of eligible invited, percentage of invited approached and percentage of approached consented throughout the study 2. Compliance rate is assessed through recording the percentage of sessions attended by participants throughout the study 3. Retention/completion rate is assessed by recording the percentage of participants completing all elements of the study throughout the duration of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Physical function is measured by the gait speed test, the sit-to-stand tests and the plantarflexion strength test at baseline, mid-intervention, immediately post-intervention and three months post-intervention 2. Heart function is measured using Non-invasive cardiac output measures (NICOM) at baseline, mid-intervention, immediately post-intervention and three months post-intervention 3. Anthropometry is measured using standard measures at baseline, mid-intervention, immediately post-intervention and three months post-intervention 4. Body composition is measured using bioelectrical impedance analysis at baseline, mid-intervention, immediately post-intervention and three months post-intervention 5. Arterial stiffness is measured using pulse wave velocity at baseline, mid-intervention, immediately post-intervention and three months post-intervention 6. Oxygen saturation is measure using a pulse oximeter at baseline, mid-intervention, immediately post-intervention and three months post-intervention 7. Habitual physical activity is measured using an accelerometer at baseline and immediately post-intervention 8. Muscle Oxygen Saturation is measured using Near-infrared spectroscopy (NIRS) between training weeks 1-2 and between training weeks 7-8 9. VO2 Peak is measured using a cardiopulmonary exercise test at baseline and immediately post-intervention 10. Urine bacterial content is analysed from a urine sample at baseline, mid-intervention and immediate post-intervention 11. Clinical parameters (co-morbidities, medication, blood test results) will be taken from medical notes at baseline, mid-intervention, immediately post-intervention and three months post-intervention 12. Blood samples for markers of immune function and inflammation and CVD risk factors will be taken via venepuncture at baseline | — |
Countries
England, United Kingdom
Contacts
Public ContactAlice Smith
Outcome results
None listed